Anal Fissure Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Anal Fissure Global Clinical Trials Review, H1, 2013" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Sezary Syndrome Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Sezary Syndrome from January 2013. It provides an overview of the number and location of trials worldwide. The report details trials by region, country, phase, status, subjects recruited, and prominent sponsors. It also profiles the top companies and universities/institutes conducting Sezary Syndrome trials.
Coronary Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Coronary Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Coronary Disease Global Clinical Trials Review, H1, 2012" provides data on the Coronary Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Liver Fibrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
Liver Fibrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Liver Fibrosis Global Clinical Trials Review, H1, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Filariasis Global Clinical Trials Review, H1, 2013ReportLinker.com
Filariasis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Filariasis Global Clinical Trials Review, H1, 2013" provides data on the Filariasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Filariasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Filariasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Asperger Syndrome Global Clinical Trials Review, H2, 2012ReportLinker.com
Asperger Syndrome Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Asperger Syndrome Global Clinical Trials Review, H2, 2012" provides data on the Asperger Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Asperger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Asperger Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Sezary Syndrome Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Sezary Syndrome from January 2013. It provides an overview of the number and location of trials worldwide. The report details trials by region, country, phase, status, subjects recruited, and prominent sponsors. It also profiles the top companies and universities/institutes conducting Sezary Syndrome trials.
Coronary Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Coronary Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Coronary Disease Global Clinical Trials Review, H1, 2012" provides data on the Coronary Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Liver Fibrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
Liver Fibrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Liver Fibrosis Global Clinical Trials Review, H1, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Filariasis Global Clinical Trials Review, H1, 2013ReportLinker.com
Filariasis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Filariasis Global Clinical Trials Review, H1, 2013" provides data on the Filariasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Filariasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Filariasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Asperger Syndrome Global Clinical Trials Review, H2, 2012ReportLinker.com
Asperger Syndrome Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Asperger Syndrome Global Clinical Trials Review, H2, 2012" provides data on the Asperger Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Asperger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Asperger Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. This outsourcing has grown as drug development has become more complex.
- When deciding whether and how to use a CRO, companies consider tactical, maximal, or strategic outsourcing based on their internal resources. Selecting the right CRO requires evaluating their capabilities, compatibility with the sponsor's needs, and costs.
- Managing the sponsor-CRO relationship is critical to ensure success. This involves clearly defining roles and responsibilities, establishing performance metrics,
Embase for pharmacovigilance: Search and validation March 22 2017Ann-Marie Roche
Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient.
Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle.
In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Ajaz Hussain
Pharmaceutical knowledge pyramid can be toppled easily!
Serendipitous intersection of Behavioral Economics & CGMP.
Why attention to Behavioral Economics can improve management of QbD work-streams?
How? What (benefits)?
Between regulatory query and response there is Design Space. In that space is our comparability protocol…
This presentation gives the details about career opportunities in clinical research, clinical research courses available in India and clinical research training.
Totality of Evidence & Theraputic Equivalence 15 October 2016Ajaz Hussain
Put R back in R&D & recognize It is a “complex” product and process!
Invest smartly in analytics, mathematics & statistics, and large sample sizes; and in systems/integrative thinking and data integration
Get to know the RLD – multiple lots; open the door with large sample size
Build capability to justify measured RLD variability is relevant to development of the proposed generic/biosimilar
Exquisite regulatory communication strategy
This is not a ‘complicated process’ for which typical “good practices” will work seamlessly (e.g., typical project management approach); this is a complex process – with multiple interactions and “emergent properties”
Treat it as it is - a complex process and plan; anticipate and address “emergent issues” - in technical, regulatory and legal dimensions; at a certain point be prepared for stakeholder (payers, patient groups,..) communications
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. They help companies that lack sufficient resources or expertise to conduct all required trials themselves.
- Selecting the right CRO is important for a successful clinical trial. Sponsors should clearly define study specifications, evaluate a CRO's capabilities and compatibility, and consider cost. Ongoing management of the sponsor-CRO relationship also impacts success.
- Common issues like selecting an inappropriate CRO, unclear study specifications from the sponsor, or poor management can lead
Finding the right medical device information in embase 11 2016Ann-Marie Roche
The document discusses guidelines for systematic reviews of biomedical literature in Clinical Evaluation Reports (CERs) for medical devices, highlighting how Embase addresses the requirements through its comprehensive indexing of devices, manufacturers, and adverse effects, as well as features for building sensitive searches. It also provides examples of searches in Embase to find information on device clinical performance, comparisons, and safety for a case study on an everolimus eluting coronary stent.
Literature screening for pharmacovigilance 190818Marnix Wieffer
This document discusses challenges in literature screening for pharmacovigilance and potential solutions. The key challenges are the high volume of scientific literature, poor signal-to-noise ratio, compliance risks for audits and inspections, duplicate articles, and increased workload from regulatory requirements. Technology solutions like automation, prioritization, text mining and machine learning can help address these challenges by improving workflow efficiency and compliance. Outsourcing literature screening services can also help reduce costs and resources needed while maintaining oversight and accountability.
Clinical research and its importance career in clinical researchRidhimaPatel2
This document is expressing the carrier opportunities in clinical research and how it important to learn clinical research for our society and the best institute providing absolute best training for the clinical research
Systemic reviews on implantable medical devices provide a quality of reportin...Pubrica
• Defining active implantable medical devices
• Literature search
• Eligibility criteria and citation screening
• Data extraction
• Reporting of device or procedure-specific data
Continue Reading: https://bit.ly/2UMYAPu
For our services: https://pubrica.com/services/research-services/systematic-review/
Why Pubrica:
When you order our services, We promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Biostatistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44-1618186353
Endometrial Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a 107-page report on endometrial cancer clinical trials in the second half of 2012. It details the number of clinical trials conducted by region, country, phase, status, subjects recruited, and leading sponsors. The report aims to give an overview of the global clinical trial landscape for endometrial cancer and benchmark trial activity and trends over time. It is available for individual purchase at a price of $2,500.
Medicines: is the applied science or practice of the diagnosis, treatment, and prevention of disease.
Bad effects called Adverse Drug Reactions (ADRs) , it differs from side effects.
Medical Device Clinical Studies and Protocol DesignMichael Swit
August 17, 2006 presentation to the IVT Medical Device Conference, focusing on the following relative to medical devices:
* Standards of Approval – What the Protocol Targets
* Key Considerations in Designing Clinical Studies
* Practical Lessons in Clinical Trial Design & Execution
Visioning the Next Decade: NIPTE-FDA CollaborationAjaz Hussain
NIPTE Seminar at US FDA, 16 March 2016.
QBR as an Organizing Principle for the Proposed NIPTE Center of Excellence for Pharmaceutical Formulations (CEPF)
The document discusses risk management and pharmacovigilance in drug development and approval. It notes that some category 2 drugs approved despite safety issues identified in trials were later withdrawn, and that post-marketing studies are important as rapid uptake and direct-to-consumer advertising can compromise new drug safety. Adverse event databases and data mining are proposed to better understand safety profiles and detect toxic signals.
This document discusses quantitative methods for signal detection in pharmacovigilance. It describes current methods like proportional reporting ratios (PRR) that measure disproportionate reporting of adverse drug reactions. Bayesian methods and log-linear models are presented as improvements. Longitudinal health records are discussed as an alternative that avoids some biases but is difficult to implement. Future directions may include using all available data on reports and incorporating pharmacokinetic properties of drugs.
This document provides an introduction to clinical trials. It defines a clinical trial as a research study performed on human subjects to determine if a new drug or therapy is both safe and effective. The document outlines the different phases of clinical trials, from pre-clinical testing on animals to post-market surveillance. It describes key terms used in clinical trials and explains the various stakeholders who are involved in and care about clinical trials, such as those in clinical development, business development, marketing, and information professionals. Finally, it discusses some of the main challenges of clinical trials, including demonstrating efficacy and safety, differentiating treatments, and getting regulatory approval.
Reconciliation and Literature Review and Signal Detection_Katalyst HLSKatalyst HLS
Introduction Reconciliation and Literature Review and Signal Detection in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. This outsourcing has grown as drug development has become more complex.
- When deciding whether and how to use a CRO, companies consider tactical, maximal, or strategic outsourcing based on their internal resources. Selecting the right CRO requires evaluating their capabilities, compatibility with the sponsor's needs, and costs.
- Managing the sponsor-CRO relationship is critical to ensure success. This involves clearly defining roles and responsibilities, establishing performance metrics,
Embase for pharmacovigilance: Search and validation March 22 2017Ann-Marie Roche
Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient.
Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle.
In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring
Behavioral Economics and Managment of Pharmaceutical QbD 25 August 2016Ajaz Hussain
Pharmaceutical knowledge pyramid can be toppled easily!
Serendipitous intersection of Behavioral Economics & CGMP.
Why attention to Behavioral Economics can improve management of QbD work-streams?
How? What (benefits)?
Between regulatory query and response there is Design Space. In that space is our comparability protocol…
This presentation gives the details about career opportunities in clinical research, clinical research courses available in India and clinical research training.
Totality of Evidence & Theraputic Equivalence 15 October 2016Ajaz Hussain
Put R back in R&D & recognize It is a “complex” product and process!
Invest smartly in analytics, mathematics & statistics, and large sample sizes; and in systems/integrative thinking and data integration
Get to know the RLD – multiple lots; open the door with large sample size
Build capability to justify measured RLD variability is relevant to development of the proposed generic/biosimilar
Exquisite regulatory communication strategy
This is not a ‘complicated process’ for which typical “good practices” will work seamlessly (e.g., typical project management approach); this is a complex process – with multiple interactions and “emergent properties”
Treat it as it is - a complex process and plan; anticipate and address “emergent issues” - in technical, regulatory and legal dimensions; at a certain point be prepared for stakeholder (payers, patient groups,..) communications
This document discusses Contract Research Organizations (CROs) and their role in supporting pharmaceutical clinical trials. It provides the following key points:
- CROs are service organizations that conduct clinical trials and other drug development work on behalf of pharmaceutical companies. They help companies that lack sufficient resources or expertise to conduct all required trials themselves.
- Selecting the right CRO is important for a successful clinical trial. Sponsors should clearly define study specifications, evaluate a CRO's capabilities and compatibility, and consider cost. Ongoing management of the sponsor-CRO relationship also impacts success.
- Common issues like selecting an inappropriate CRO, unclear study specifications from the sponsor, or poor management can lead
Finding the right medical device information in embase 11 2016Ann-Marie Roche
The document discusses guidelines for systematic reviews of biomedical literature in Clinical Evaluation Reports (CERs) for medical devices, highlighting how Embase addresses the requirements through its comprehensive indexing of devices, manufacturers, and adverse effects, as well as features for building sensitive searches. It also provides examples of searches in Embase to find information on device clinical performance, comparisons, and safety for a case study on an everolimus eluting coronary stent.
Literature screening for pharmacovigilance 190818Marnix Wieffer
This document discusses challenges in literature screening for pharmacovigilance and potential solutions. The key challenges are the high volume of scientific literature, poor signal-to-noise ratio, compliance risks for audits and inspections, duplicate articles, and increased workload from regulatory requirements. Technology solutions like automation, prioritization, text mining and machine learning can help address these challenges by improving workflow efficiency and compliance. Outsourcing literature screening services can also help reduce costs and resources needed while maintaining oversight and accountability.
Clinical research and its importance career in clinical researchRidhimaPatel2
This document is expressing the carrier opportunities in clinical research and how it important to learn clinical research for our society and the best institute providing absolute best training for the clinical research
Systemic reviews on implantable medical devices provide a quality of reportin...Pubrica
• Defining active implantable medical devices
• Literature search
• Eligibility criteria and citation screening
• Data extraction
• Reporting of device or procedure-specific data
Continue Reading: https://bit.ly/2UMYAPu
For our services: https://pubrica.com/services/research-services/systematic-review/
Why Pubrica:
When you order our services, We promise you the following – Plagiarism free | always on Time | 24*7 customer support | Written to international Standard | Unlimited Revisions support | Medical writing Expert | Publication Support | Biostatistical experts | High-quality Subject Matter Experts.
Contact us:
Web: https://pubrica.com/
Blog: https://pubrica.com/academy/
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United Kingdom: +44-1618186353
Endometrial Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a 107-page report on endometrial cancer clinical trials in the second half of 2012. It details the number of clinical trials conducted by region, country, phase, status, subjects recruited, and leading sponsors. The report aims to give an overview of the global clinical trial landscape for endometrial cancer and benchmark trial activity and trends over time. It is available for individual purchase at a price of $2,500.
Medicines: is the applied science or practice of the diagnosis, treatment, and prevention of disease.
Bad effects called Adverse Drug Reactions (ADRs) , it differs from side effects.
Medical Device Clinical Studies and Protocol DesignMichael Swit
August 17, 2006 presentation to the IVT Medical Device Conference, focusing on the following relative to medical devices:
* Standards of Approval – What the Protocol Targets
* Key Considerations in Designing Clinical Studies
* Practical Lessons in Clinical Trial Design & Execution
Visioning the Next Decade: NIPTE-FDA CollaborationAjaz Hussain
NIPTE Seminar at US FDA, 16 March 2016.
QBR as an Organizing Principle for the Proposed NIPTE Center of Excellence for Pharmaceutical Formulations (CEPF)
The document discusses risk management and pharmacovigilance in drug development and approval. It notes that some category 2 drugs approved despite safety issues identified in trials were later withdrawn, and that post-marketing studies are important as rapid uptake and direct-to-consumer advertising can compromise new drug safety. Adverse event databases and data mining are proposed to better understand safety profiles and detect toxic signals.
This document discusses quantitative methods for signal detection in pharmacovigilance. It describes current methods like proportional reporting ratios (PRR) that measure disproportionate reporting of adverse drug reactions. Bayesian methods and log-linear models are presented as improvements. Longitudinal health records are discussed as an alternative that avoids some biases but is difficult to implement. Future directions may include using all available data on reports and incorporating pharmacokinetic properties of drugs.
This document provides an introduction to clinical trials. It defines a clinical trial as a research study performed on human subjects to determine if a new drug or therapy is both safe and effective. The document outlines the different phases of clinical trials, from pre-clinical testing on animals to post-market surveillance. It describes key terms used in clinical trials and explains the various stakeholders who are involved in and care about clinical trials, such as those in clinical development, business development, marketing, and information professionals. Finally, it discusses some of the main challenges of clinical trials, including demonstrating efficacy and safety, differentiating treatments, and getting regulatory approval.
Reconciliation and Literature Review and Signal Detection_Katalyst HLSKatalyst HLS
Introduction Reconciliation and Literature Review and Signal Detection in Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report from GlobalData on clinical trials for abdominal aortic aneurysms. The report provides data on over 100 clinical trials conducted between 2007-2012, including regional breakdown of trials, top sponsoring companies and universities, prominent drugs being tested, and trends in trial enrollment numbers over time. The report aims to give readers an overview of experimental treatments and global research activity for abdominal aortic aneurysms.
Congenital Heart Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Congenital Heart Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Congenital Heart Disease Global Clinical Trials Review, H1, 2012" provides data on the Congenital Heart Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congenital Heart Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Congenital Heart Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acute Lung Injury Global Clinical Trials Review, H2, 2012ReportLinker.com
Acute Lung Injury Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Acute Lung Injury Global Clinical Trials Review, H2, 2012" provides data on the Acute Lung Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Lung Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The document provides an overview and analysis of clinical trials being conducted for ulcers on a global level in the first half of 2014. It summarizes the number of trials by region, with the most trials occurring in Asia-Pacific and Europe. The report also outlines the top countries contributing trials for each region and details clinical trials by phase, status, sponsor type, and recruited subjects over time. It concludes with profiles of prominent companies and institutions conducting ulcer trials.
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on clinical trials for left ventricular dysfunction from 2012. It includes statistics on 97 clinical trials by region, country, phase, sponsor, and drug. The report gives an overview of trial recruitment status and numbers globally, and lists the top contributing countries, sponsors, and universities to left ventricular dysfunction trials in 2012.
Integra gen s.a (alint) product pipeline analysis, 2014 updateAmbikabasa
Summary IntegraGen S.A (IntegraGen) is a biotechnology service provider. The company provides clinical genomic services to academic researchers and life sciences companies. It offers services such as DNA extraction, management samples, study design, strategy, selection markers, tagging, biostatistics analysis, and bioinformatics analysis of sequence data. IntegraGen provides sequencing and genotyping of DNA and RNA. The company offers services in the fields of pharmacogenetics, cytogenetics, epigenetics, and agriculture. It serves patients, clinicians and researchers. IntegraGen partners with illumia, Fluidigm, DNA genotek and Agitent Certified companies.
http://www.researchmoz.us/integragen-sa-alint-product-pipeline-analysis-2014-update-report.html
Gastric Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on gastric cancer clinical trials in the second half of 2012. It includes 123 pages of data on over 1,000 clinical trials conducted globally, including information on the number and location of trials, participating companies and institutions, trial status and recruitment numbers. The report is available for purchase for $2,500 and provides detailed insight into ongoing and discontinued gastric cancer trials worldwide.
Clinical Affairs Excellence: Benchmarking Clinical Trial Strategies To Ensure...Best Practices
This document summarizes the findings of a benchmarking study conducted by Best Practices, LLC on clinical trial strategies for medical device companies. Key findings include:
- The average medical device company in the study had $3.8 billion in annual revenue and spent $39 million (1.1% of revenue) on clinical affairs.
- Most device companies conducted the majority (72%) of clinical trials in-house, with 22% outsourced and 4% offshore. Pharma companies outsourced more activities.
- Regulators had extensive questions about outside the US trial data for 46% of device companies and 38% felt data led to extensive regulatory conversations.
- Device companies did not out
Global Uro-Gynecological Surgical Devices IndustryReportLinker.com
This report analyzes the worldwide markets for Uro-Gynecological Surgical Devices in US$ Million by the following segments: Urological Surgical Devices (Sling & Suspension Devices, & Other Urological Devices), and Gynecological Surgical Devices (Endometrial Ablation Devices, Endoscopes, Hysteroscope Systems, Fluid Management Systems, & Other Gynecological Devices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia'Pacific, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 66 companies including many key and niche players such as Gyrus ACMI Corporation, American Medical Systems Holdings Incorporated, Boston Scientific Corporation, C. R. Bard, Inc., Cook Urological Inc., CooperSurgical, Inc., Hologic Inc., Ethicon, Inc., Cytyc Corporation, Cytyc Surgical Products, Ethicon Inc., Karl Storz GmbH & Co. KG, MDMI Technologies, Inc., Medtronic, Inc., Olympus America Inc., Olympus Surgical & Industrial America, Inc., Richard Wolf GmbH, and Stryker Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global MarketsReportsnReports
This report analyzes the global market for nucleic acid aptamers used for diagnostics and therapeutics. It provides an overview of aptamer applications, analyzes market trends from 2011-2017, and identifies high-growth segments. The 138-page report was published in October 2012 and costs $4,850 for a single-user license. It examines technology growth opportunities for aptamers and profiles major industry players.
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012ReportsnReports
This document provides a 139-page report on global clinical trials for kidney cancer (renal cell cancer) in the second half of 2012. It includes data on the number and location of clinical trials, breakdown of trials by phase, status, subject recruitment, and leading sponsors. The report aims to give an overview of the clinical trial landscape and assess trends in research and development for treating kidney cancer worldwide.
This white paper discusses four ways that pharmaceutical and biotechnology companies can accelerate their clinical portfolio strategy using advanced analytics and clinical trial data and technology. It provides examples of how visualizing clinical trial data over time, benchmarking trial durations, mapping competitive drug pipelines, and comparing safety profiles across trials can provide insights to help with strategic decision making regarding clinical development.
The document discusses the process and costs associated with drug development. It notes that the average cost to develop a new drug is $350 million to $5.5 billion and the process takes 6.5-7 years from discovery to approval. Key barriers to drug development include high financial costs, lengthy timelines for clinical trials, and regulatory hurdles. Approaches to reduce costs and timelines include greater use of electronic health records, simplifying clinical trial protocols, and utilizing decentralized clinical trial models.
Similar to Anal Fissure Global Clinical Trials Review, H1, 2013 (20)
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
This document provides a summary and table of contents of the "World Biomass Report" published in November 2012. The report examines the global biomass market and finds that while it suffered during the economic downturn due to low coal prices and supply issues, the sector began growing again in 2010 as coal prices rose. Most biomass plants rely on wood pellets imported from North America, though suppliers from other regions like Russia and Australia aim to compete in the market. The full report contains detailed information on biomass resources, technologies, logistics, investments and policies on a global and national level.
This report provides an overview of the global biofuels industry in 2012. It summarizes production and policies related to first, second, and third generation biofuels in countries around the world. The report finds that 2009 was a difficult year for the biofuels industry due to low oil prices and reduced demand. However, projects using diverse feedstocks or next generation technologies like cellulosics and algae continued to receive investment. The report includes sections on biofuel production trends, technologies, environmental impacts, and policies in regions like Europe, the USA, and individual European countries.
This report analyzes the current state of various renewable energy technologies including hydropower, wind, solar, biomass, biofuels, and geothermal. It examines the market size and outlook for each technology by region, discusses the advantages and disadvantages of different renewable sources, and assesses the development status and future potential of the renewable energy industry globally. The report also profiles major renewable energy companies and evaluates government policies and industry support programs around the world.
This report provides an overview of the global solar photovoltaic (PV) market. It outlines key industry data like global solar capacity, production figures, and forecasts for future growth. It also examines major country markets and discusses the advantages, challenges, and components of the solar PV industry. The report analyzes factors such as government incentives, technology developments, and manufacturing trends that are shaping the future of the solar industry.
Anal Fissure Global Clinical Trials Review, H1, 2013
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Anal Fissure Global Clinical Trials Review, H1, 2013
Published on January 2013
Report Summary
Anal Fissure Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Anal Fissure Global Clinical Trials Review, H1, 2013" provides data on the Anal Fissure clinical trial
scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of
the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary
coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the
number of trials for the key drugs for treating Anal Fissure. This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and
Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Content
Table of Contents
Table of CContents 2
List of Tables 4
List of Figures 5
Introduction 6
Anal Fissure 6
Report Guidance 6
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 1/7
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by BRIC Nations 14
Clinical Trials by G7 Nations 15
Clinical Trials in G7 Nations by Trial Status 16
Clinical Trials by E7 Nations 17
Clinical Trials in E7 Nations by Trial Status 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Unaccomplished Trials of Anal Fissure 22
Subjects Recruited Over a Period of Time 23
Prominent Sponsors 24
Top Companies Participating in Anal Fissure Therapeutics Clinical Trials 26
Prominent Drug Comparison 28
Clinical Trial Profiles 29
Clinical Trial Overview of Top Companies 29
Troikaa Pharmaceuticals Ltd. 29
Clinical Trial Overview of Troikaa Pharmaceuticals Ltd. 29
S.L.A. Pharma AG 30
Clinical Trial Overview of S.L.A. Pharma AG 30
Ipsen S.A. 31
Clinical Trial Overview of Ipsen S.A. 31
Solvay Pharmaceuticals, Inc. 32
Clinical Trial Overview of Solvay Pharmaceuticals, Inc. 32
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Dizney Display Company 34
Clinical Trial Overview of Dizney Display Company 34
SOFAR SPA 35
Clinical Trial Overview of SOFAR SPA 35
SLA Pharma 36
Clinical Trial Overview of SLA Pharma 36
TECNIMEDE - Sociedade Tecnico-Medicinal, S.A. 37
Clinical Trial Overview of TECNIMEDE - Sociedade Tecnico-Medicinal, S.A. 37
Ventrus Biosciences, Inc. 38
Clinical Trial Overview of Ventrus Biosciences, Inc. 38
ProStrakan Group plc 39
Clinical Trial Overview of ProStrakan Group plc 39
RDD Pharma Ltd. 40
Clinical Trial Overview of RDD Pharma Ltd. 40
Clinical Trial Overview of Top Universities / Institutes / Hospitals 41
Onze Lieve Vrouwe Gasthuis 41
Clinical Trial Overview of Onze Lieve Vrouwe Gasthuis 41
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 2/7
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Ankara University 42
Clinical Trial Overview of Ankara University 42
University of Navarra 43
Clinical Trial Overview of University of Navarra 43
Huazhong University of Science & Technology 44
Clinical Trial Overview of Huazhong University of Science & Technology 44
Universita degli Studi di Palermo 45
Clinical Trial Overview of Universita degli Studi di Palermo 45
Hadassah Medical Organization 46
Clinical Trial Overview of Hadassah Medical Organization 46
Policlinico Universitario "Agostino Gemelli" 47
Clinical Trial Overview of Policlinico Universitario "Agostino Gemelli" 47
Research committee of Hamedan University of Medical Sciences 48
Clinical Trial Overview of Research committee of Hamedan University of Medical Sciences 48
Bushehr University of Medical Sciences 49
Clinical Trial Overview of Bushehr University of Medical Sciences 49
Birjand University of Medical Sciences 50
Clinical Trial Overview of Birjand University of Medical Sciences 50
Institute of Child and Mother Health 51
Clinical Trial Overview of Institute of Child and Mother Health 51
Hospital del Mar 52
Clinical Trial Overview of Hospital del Mar 52
Mazandaran University of Medical Sciences 53
Clinical Trial Overview of Mazandaran University of Medical Sciences 53
SB Istanbul Education and Research Hospital 54
Clinical Trial Overview of SB Istanbul Education and Research Hospital 54
Rikshospitalet University Hospital 55
Clinical Trial Overview of Rikshospitalet University Hospital 55
Five Key Clinical Profiles 56
Appendix 83
Abbreviations 83
Definitions 83
Research Methodology 84
Secondary Research 84
About GlobalData 85
Contact Us 85
Disclaimer 85
Source 86
List of Tables
Anal Fissure Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Anal Fissure Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Anal Fissure Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Anal Fissure Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2013* 10
Anal Fissure Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 3/7
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Anal Fissure Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Anal Fissure Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2013* 13
Anal Fissure Therapeutics Clinical Trials, BRIC Countries, 2013* 14
Anal Fissure Therapeutics Clinical Trials, G7 Countries, 2013* 15
Anal Fissure Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 16
Anal Fissure Therapeutics Clinical Trials, E7 Countries, 2013* 17
Anal Fissure Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 18
Anal Fissure Therapeutics Market, Global, Clinical Trials by Phase, 2013* 19
Anal Fissure Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 20
Anal Fissure Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 21
Anal Fissure Therapeutics Market, Global, Terminated Clinical Trials, 2013* 22
Anal Fissure Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 23
Anal Fissure Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 25
Anal Fissure Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 27
Anal Fissure Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 28
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Troikaa Pharmaceuticals Ltd., 2013* 29
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by S.L.A. Pharma AG, 2013* 30
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Ipsen S.A., 2013* 31
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Solvay Pharmaceuticals, Inc., 2013* 32
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 33
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Dizney Display Company, 2013* 34
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by SOFAR SPA, 2013* 35
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by SLA Pharma, 2013* 36
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by TECNIMEDE - Sociedade Tecnico-Medicinal, S.A., 2013*
37
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Ventrus Biosciences, Inc., 2013* 38
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by ProStrakan Group plc, 2013* 39
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by RDD Pharma Ltd., 2013* 40
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Onze Lieve Vrouwe Gasthuis, 2013* 41
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Ankara University, 2013* 42
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Navarra, 2013* 43
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Huazhong University of Science & Technology, 2013* 44
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Universita degli Studi di Palermo, 2013* 45
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Hadassah Medical Organization, 2013* 46
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Policlinico Universitario "Agostino Gemelli", 2013* 47
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Research committee of Hamedan University of Medical
Sciences, 2013* 48
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Bushehr University of Medical Sciences, 2013* 49
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Birjand University of Medical Sciences, 2013* 50
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Institute of Child and Mother Health, 2013* 51
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital del Mar, 2013* 52
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Mazandaran University of Medical Sciences, 2013* 53
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by SB Istanbul Education and Research Hospital, 2013* 54
Anal Fissure Therapeutics Clinical Trials Market, Global, Clinical Trials by Rikshospitalet University Hospital, 2013* 55
List of Figures
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 4/7
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Anal Fissure Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Anal Fissure Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Anal Fissure Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Anal Fissure Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2013* 10
Anal Fissure Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Anal Fissure Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2013* 13
Anal Fissure Therapeutics Clinical Trials, BRIC Countries (%), 2013* 14
Anal Fissure Therapeutics Clinical Trials, G7 Countries (%), 2013* 15
Anal Fissure Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 16
Anal Fissure Therapeutics Clinical Trials, E7 Countries (%), 2013* 17
Anal Fissure Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 18
Anal Fissure Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 19
Anal Fissure Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 20
Anal Fissure Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 21
Anal Fissure Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 23
Anal Fissure Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 24
Anal Fissure Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 26
Anal Fissure Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 28
GlobalData Methodology 84
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 5/7
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Anal Fissure Global Clinical Trials Review, H1, 2013
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 500.00 Quantity: _____
Site License--USD 5 000.00 Quantity: _____
Corporate License--USD 7 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 6/7
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Anal Fissure Global Clinical Trials Review, H1, 2013 (From Slideshare) Page 7/7